Don't fret about Lilly's 3rd-to-market start in CGRP, exec says. It's got big plans in migraine and pain, too

Eli Lilly's Emgality didn't take the first-to-market crown in the budding CGRP field of migraine prevention drugs. It didn't even come in second. But a top exec believes Lilly has what it takes to make Emgality not only stand out from the crowd, but become the cornerstone of a migraine and pain franchise.